Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022
CONCLUSION: The ASCO/FoCR/FDA task force recommendations were associated with a shift in patterns of brain metastases exclusion criteria from conditionally excluded to not excluded. These findings demonstrate that the cancer clinical trial community has begun to change the way trials are written to be more inclusive.PMID:38537158 | DOI:10.1200/JCO.23.01777 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Hong Xiao Riha Vaidya Dawn L Hershman Joseph M Unger Source Type: research
Treatment of Bone Metastases of Breast Cancer With 177Lu-DOTA-IBA
We report a case of recurrent intermittent pain due to bone metastasis, who demonstrated a satisfactory therapy response after 2 cycles of 177Lu-DOTA-IBA. In addition, the patient did not have any observable adverse effects.PMID:38537210 | DOI:10.1097/RLU.0000000000005193 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Jia Deng Jian Yang Zixuan Cheng Yue Chen Source Type: research
68Ga-DOTA-IBA Uptake in Breast cancer
Clin Nucl Med. 2024 Mar 25. doi: 10.1097/RLU.0000000000005200. Online ahead of print.ABSTRACTA 77-year-old woman with recently diagnosed breast cancer underwent 68Ga-labeled DOTA-ibandronic acid (68Ga-DOTA-IBA) PET/CT scan for the evaluation of bone metastases. The examination revealed increased tracer uptake, indicating that the cervical vertebrae presented osteoblastic metastasis. Interestingly, the breast cancer also showed enhanced activity of 68Ga-DOTA-IBA.PMID:38537211 | DOI:10.1097/RLU.0000000000005200 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Feifan Xiang Huipan Liu Xiaoqi Tan Yue Chen Source Type: research
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
CONCLUSION: This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.PMID:38528295 | DOI:10.1007/s10147-024-02492-5 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Della Varghese Giovanna I Cruz Colden Johanson Liz Toland Miguel Miranda Eleanor C Faherty David Harland Henry G Kaplan Source Type: research
Treatment withdrawal experiences of women with breast cancer: A phenomenological study
CONCLUSION: Women's behaviours became transformed by suffering. Actions were influenced by physical and psychological distress, misconceptions about treatments, and appearance changes by self-determination through self-protection.RELEVANCE TO CLINICAL PRACTICE: Healthcare professionals should respect women's autonomy and work collaboratively to ensure their decision-making with accurate information and awareness of the potential risks and benefits of treatment withdrawal need to concern.PMID:38528376 | DOI:10.1111/jocn.17142 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Shu-Ching Chi Yu-Chen Liu Sriyani Padmalatha Konara Mudiyanselage Susan Fetzer Mei-Feng Lin Source Type: research
Pharmacological suppression of the OTUD4-CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
J Clin Invest. 2024 Mar 26:e176390. doi: 10.1172/JCI176390. Online ahead of print.ABSTRACTDespite widespread utilization of immunotherapy, challenge to treat immune-cold tumors needs to be resolved. Multiomic analyses and experimental validation identified the OTUD4-CD73 proteolytic axis as a promising target in treating immune-suppressive triple negative breast cancer (TNBC). Mechanistically, deubiquitylation of CD73 by OTUD4 counteracted its ubiquitylation by TRIM21, resulting in CD73 stabilization that inhibits tumor immune responses. We further demonstrated the importance of TGF-β signaling for orchestrating the OTUD4...
Source: Clinical Breast Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Yueming Zhu Anupam Banerjee Ping Xie Andrey A Ivanov Amad Uddin Qiao Jiao Junlong J Chi Lidan Zeng Ji Young Lee Yifan Xue Xinghua Lu Massimo Cristofanilli William J Gradishar Curtis J Henry Theresa W Gillespie Manali Ajay Bhave Kevin Kalinsky Haian Fu Ive Source Type: research
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
CONCLUSION: This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.PMID:38528295 | DOI:10.1007/s10147-024-02492-5 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Della Varghese Giovanna I Cruz Colden Johanson Liz Toland Miguel Miranda Eleanor C Faherty David Harland Henry G Kaplan Source Type: research
Treatment withdrawal experiences of women with breast cancer: A phenomenological study
CONCLUSION: Women's behaviours became transformed by suffering. Actions were influenced by physical and psychological distress, misconceptions about treatments, and appearance changes by self-determination through self-protection.RELEVANCE TO CLINICAL PRACTICE: Healthcare professionals should respect women's autonomy and work collaboratively to ensure their decision-making with accurate information and awareness of the potential risks and benefits of treatment withdrawal need to concern.PMID:38528376 | DOI:10.1111/jocn.17142 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Shu-Ching Chi Yu-Chen Liu Sriyani Padmalatha Konara Mudiyanselage Susan Fetzer Mei-Feng Lin Source Type: research
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer
CONCLUSION: Our finding revealed that local anesthetic ropivacaine attenuated breast cancer stemness through AKT1/GGT1/NF-κB signaling pathway, suggesting the potential clinical value of ropivacaine in breast cancer treatment.PMID:38523299 | PMC:PMC10962119 | DOI:10.1186/s13046-024-03016-9 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Lin Ding Hui Jiang Qiangwei Li Qiushuang Li Tian-Tian Zhang Limeng Shang Bin Xie Yaling Zhu Keshuo Ding Xuanming Shi Tao Zhu Yong Zhu Source Type: research
Breast Cancer Risk Factors among Women with Solid Breast Lesions
CONCLUSIONS: Age and BMI were observed to be the most significant factors for breast cancer risk increase, followed by living in a rural area. A family history of breast cancer was shown to be inversely correlated with cancer risk increase.PMID:38525715 | PMC:PMC10961805 | DOI:10.3390/clinpract14020036 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Ivana Eremici Andreea Borlea Catalin Dumitru Dana Stoian Source Type: research
The Role of Illness Perception and Self-Efficacy in Determining Quality of Life among Cancer Patients
CONCLUSIONS: The findings underscore the vital role of nurses and healthcare providers in aiding cancer patients to develop and utilize self-management strategies effectively. The study reveals that a patient's capacity to manage their illness is significantly influenced by their confidence, understanding of their condition, and overall quality of life. Addressing these aspects can greatly enhance healthcare professionals' contribution to improving the resilience and well-being of individuals battling cancer.PMID:38525717 | PMC:PMC10961753 | DOI:10.3390/clinpract14020038 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Aisha Alhofaian Marym M Alaamri Mariam Ahmed Abdalmajeed Lama Saeed Wadaah Leena Abdulaziz Aljuhani Meral Ammar Amin Afnan Tunsi Ruba Alharazi Source Type: research
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
CONCLUSIONS: Both Day 2 and Days 3-5 were weakly recommended for pegylated G-CSF administration post-chemotherapy in patients with cancer. The limited evidence highlights the need for further research to refine recommendations.PMID:38526621 | DOI:10.1007/s10147-024-02499-y (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Yukinori Ozaki Takamichi Yokoe Tetsuhiro Yoshinami Kazuki Nozawa Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Yuji Miura Makoto Endo Shingo Yano Dai Maruyama Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito Eishi Baba Nobuaki Ochi Toshio K Source Type: research
Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway
CONCLUSION: OPN promoted tumor sphere formation and angiogenesis in TNBC by activating the PI3K/AKT/mTOR pathway to regulate GPX4-mediated anti-lipid peroxidation levels.PMID:38526702 | DOI:10.1007/s00432-024-05658-w (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Man Guo Mengyue Liu Weihan Li Cao Wang Lu Zhang Hao Zhang Source Type: research
Emerging measurements for tumor-infiltrating lymphocytes in breast cancer
Jpn J Clin Oncol. 2024 Mar 23:hyae033. doi: 10.1093/jjco/hyae033. Online ahead of print.ABSTRACTTumor-infiltrating lymphocytes are a general term for lymphocytes or immune cells infiltrating the tumor microenvironment. Numerous studies have demonstrated tumor-infiltrating lymphocytes to be robust prognostic and predictive biomarkers in breast cancer. Recently, immune checkpoint inhibitors, which directly target tumor-infiltrating lymphocytes, have become part of standard of care treatment for triple-negative breast cancer. Surprisingly, tumor-infiltrating lymphocytes quantified by conventional methods do not predict respon...
Source: Clinical Breast Cancer - March 24, 2024 Category: Cancer & Oncology Authors: Rongrong Wu Yoshiya Horimoto Masanori Oshi Matthew G K Benesch Thaer Khoury Kazuaki Takabe Takashi Ishikawa Source Type: research
Skin marker combined with surface-guided auto-positioning for breast DIBH radiotherapy daily initial patient setup: An optimal schedule for both accuracy and efficiency
CONCLUSION: SGRT one-key calibration was found to be more suitable when followed by skin marker/tattoo and in-room laser positioning, establishing it as an optimal daily initial set-up protocol for breast DIBH radiotherapy. This modality also proved to be suitable for free-breathing breast cancer radiotherapy, and its widespread clinical use is recommended.PMID:38522035 | DOI:10.1002/acm2.14319 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 24, 2024 Category: Cancer & Oncology Authors: Jianjun Lai Zhizeng Luo Lu Jiang Haili Hu Chang Gao Chuanfeng Zhang Liting Chen Jing Wu Zhibing Wu Source Type: research
